Compare RZLT & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RZLT | SOPH |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 471.0M | 462.3M |
| IPO Year | 2011 | 2021 |
| Metric | RZLT | SOPH |
|---|---|---|
| Price | $3.84 | $7.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $9.80 | $9.75 |
| AVG Volume (30 Days) | ★ 1.5M | 524.7K |
| Earning Date | 11-17-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.25 |
| Revenue Next Year | $2,214.20 | $24.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $3.83 |
| 52 Week High | $11.46 | $8.98 |
| Indicator | RZLT | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 44.36 |
| Support Level | $3.58 | $4.58 |
| Resistance Level | $4.09 | $8.80 |
| Average True Range (ATR) | 0.30 | 0.47 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 36.47 | 44.75 |
Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.